Q3 EPS Estimate for ACADIA Pharmaceuticals Lifted by Analyst

Key Points

• HC Wainwright has raised its earnings per share (EPS) estimate for ACADIA Pharmaceuticals for Q3 2025 to $0.22, up from a previous estimate of $0.17, maintaining a "Buy" rating with a price target of $32.00.
• ACADIA Pharmaceuticals reported a Q2 EPS of $0.16, exceeding consensus estimates, with revenue increasing by 9.4% year-over-year to $264.57 million.
• Stock analysts have given ACADIA a moderate buy rating, with the average price target currently standing at $28.88, amidst varied projections from other firms.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Research analysts at HC Wainwright raised their Q3 2025 EPS estimates for ACADIA Pharmaceuticals in a report released on Thursday, August 7th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will post earnings per share of $0.22 for the quarter, up from their previous forecast of $0.17. HC Wainwright has a "Buy" rating and a $32.00 price target on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' Q4 2025 earnings at $0.27 EPS, FY2025 earnings at $0.76 EPS and FY2026 earnings at $1.93 EPS.

A number of other research analysts have also commented on ACAD. Deutsche Bank Aktiengesellschaft upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating and lifted their price objective for the company from $20.00 to $35.00 in a research note on Wednesday, May 21st. Oppenheimer reaffirmed a "market perform" rating and set a $22.00 price objective (up from $19.00) on shares of ACADIA Pharmaceuticals in a research note on Thursday, June 26th. Royal Bank Of Canada increased their price objective on ACADIA Pharmaceuticals from $39.00 to $40.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. Needham & Company LLC reissued a "buy" rating and issued a $30.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, June 26th. Finally, Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $28.88.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ:ACAD traded up $0.63 during trading on Monday, hitting $25.45. 3,651,511 shares of the company were exchanged, compared to its average volume of 2,183,071. The stock has a market capitalization of $4.29 billion, a P/E ratio of 19.14, a PEG ratio of 6.72 and a beta of 0.70. The firm's 50 day moving average price is $22.45 and its 200-day moving average price is $19.32. ACADIA Pharmaceuticals has a 12-month low of $13.40 and a 12-month high of $25.88.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.02. The company had revenue of $264.57 million for the quarter, compared to analysts' expectations of $263.07 million. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the company earned $0.20 earnings per share.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,000 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $22.50, for a total value of $90,000.00. Following the transaction, the insider directly owned 20,395 shares in the company, valued at approximately $458,887.50. This represents a 16.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mark C. Schneyer sold 2,000 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. Following the completion of the transaction, the executive vice president owned 62,130 shares in the company, valued at approximately $1,553,250. This trade represents a 3.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,446 shares of company stock worth $454,634. 28.30% of the stock is owned by insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Exchange Traded Concepts LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the first quarter worth approximately $29,000. Banque Transatlantique SA acquired a new position in ACADIA Pharmaceuticals during the first quarter valued at approximately $31,000. Picton Mahoney Asset Management purchased a new stake in shares of ACADIA Pharmaceuticals during the first quarter valued at approximately $32,000. Federated Hermes Inc. raised its stake in shares of ACADIA Pharmaceuticals by 231.5% during the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 1,618 shares during the period. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $39,000. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.